Scalper1 News
Five initial public offerings slated for the week of June 8 plan to raise $471 million, led by Axovant Sciences, a developer of treatments for Alzheimer’s disease and other forms of dementia. Two other health-related IPOs are in the lineup, as is a bank and restaurant chain. Axovant could be the fifth biotech of 2015 to command a market cap valuation of more than $1 billion, reports IPO ETF manager Renaissance Capital. Last year, it says, just two Scalper1 News
Scalper1 News